Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

NCT02711228 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

26

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immune Deficiency
Secondary Immune Deficiency

Interventions

BIOLOGICAL: Subcutaneous Immune Globulin (Human) (Hizentra)

Sponsor

CSL Behring